Contribute Try STAT+ Today

Rise and shine, everyone, another busy day is on the way. This is the middle of the week, after all, which means congratulations are in order. How so? You made it this far, so why not forge ahead? Of course, no effort would be complete without a few cups of stimulation. We are relying on chocolate mocha, for those keeping track. Feel free to indulge along with us. Remember, no prescription is required. Meanwhile, here are some tidbits to get you going. Have a lovely day, and do keep in touch. …

Three-quarters of Americans believe the U.S. government should start donating Covid-19 to other countries, but only after every American who wants a vaccine has received one, according to the latest survey from STAT and The Harris Poll. At the same time, slightly more than half of Americans believe Washington should immediately start donating vaccines to other countries in order to achieve global herd immunity, which reflects growing concern that the coronavirus cannot be contained until most of the world is vaccinated.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.